Previous genome-wide association studies for CKD in African Americans identified 2 alleles (termed G1 and G2) in apolipoprotein L1 (APOL1) that significantly increased the burden of renal disease. [5] [6] [7] The APOL1 G1 allele consists of 2 missense mutations (p.S342G, p.I384M); the G2 allele is a 2 amino-acid deletion (residues 388 and 389). Both G1 and G2 APOL1 alleles enhance lysis of Trypanosoma brucei rhodesiense, conveying resistance to African sleeping sickness. 6 Positive selection for this protection against African sleeping sickness explains the high frequency of G1 and G2 alleles in individuals with African ancestry and their complete absence in individuals of European ancestry. A recent analysis of the burden of APOL1 risk alleles among 1825 African American participants in the Dallas Heart Study showed that 1.7% individuals with CKD had 1 or no APOL1 risk alleles, whereas 6.7% of individuals with CKD had 2 risk alleles, suggesting a recessive model of disease pathogenesis. 8 Because ≈36% of Americans with African ancestry carry either the G1 or G2 allele and 14% carry 2 APOL1 risk alleles, 5, 6 the increased burden of CKD in African Americans is largely explained by APOL1 genotypes. Mechanisms by which APOL1 alleles increase CKD risk are still unknown.
Because CKD confers greater risk for CVD in Americans of African than European ancestry, we hypothesized that APOL1 alleles G1 and G2 contribute to the increased CVD risk observed in African Americans. This hypothesis seemed biologically plausible because APOL1 is a major apolipoprotein component of dense high-density lipoprotein (HDL3) particles that play a central role in cholesterol transport and attenuate low-density lipoprotein (LDL) oxidation. 9 HDL levels are associated with CVD risk, but whether this relationship reflects concomitant abnormalities in other lipid levels (particularly LDL) 10, 11 or pleiotropic HDL functions (eg, cholesterol efflux, insulin secretion) 12, 13 remains controversial.
In this study, we defined the allelic spectrum of the APOL1 gene in 1959 unrelated individuals from the Jackson Heart Study (JHS) cohort and assessed the association of common and rare alleles with CKD and CVD. We replicated results using exome sequence data from 749 African ancestry participants from the Women's Health Initiative (WHI) cohort ( Figure 1 ).
Methods

Study Subjects
APOL1 was sequenced in participants enrolled in the JHS (dbGaP Study Accession phs000286.v3.p1). The JHS is a large, communitybased, observational study whose participants were recruited from urban and rural areas of the Jackson, MS, metropolitan statistical area. 14 Further details are provided in the Online Methods. These studies were performed using protocols approved by the JHS, institutional ethics committees, and with informed consent from all participants.
Replication studies were performed by analyses of participants of African ancestry from the WHI clinical trial (dbGaP Study Accession phs000200.v1.p1). The WHI recruited and followed 161 808 postmenopausal women aged 50 to 79 years at 40 clinical centers across the United States from 1993 to 1998. 15 The WHI eligibility criteria included the ability to complete study visits with expected survival and local residency for ≥3 years. Enrollment criteria excluded individuals with advanced kidney disease. These studies were performed using protocols approved by the WHI, institutional ethics committees, and with informed consent from all participants. CVD risk factors, including age, sex, body mass index (BMI), diabetes mellitus status, hypertension status, smoking status, and renal function, were assessed in all study participants. In JHS participants, clinical histories of stroke, cardiac surgery and arterial catheterization, cardiac computerized tomography with Agatston coronary artery calcium scores were assessed. In WHI participants, stroke and adjudicated cardiovascular event-free survival were assessed. Additional details are provided in the Online Methods.
Genotype Ascertainment
Coding exons of the APOL1 gene were sequenced using a custom hybrid capture array for JHS participants as previously described 16 Nonstandard Abbreviations and Acronyms and detailed in the Online Methods. WHI samples were exome sequenced as part of the NHLBI Grand Opportunity Exome Sequencing Project as previously described. 17 All JHS and WHI samples were also genotyped on the Affymetrix Genome-Wide Human SNP Array 6.0. We computed concordance of sequence genotypes with these singlenucleotide polymorphism array genotypes using the PLINK software package. 18 Principal component analysis was performed using PLINK and EIGENSTRAT (Online Figure I) . 19 These analyses verified that all individuals were unrelated and were of African ancestry. Quality control showed high (>96%) concordance between sequence and singlenucleotide polymorphism array genotypes for the same individuals.
Statistical Comparison of Variant Carrier Phenotypes
We assessed association between and variant carrier status using the Fisher exact test, logistic regression adjusted for covariates, and Cox proportional hazard models as specified. Statistical analysis was conducted with the R software package.
Results
DNA sequence analysis of the APOL1 gene in 1959 JHS participants identified 32 nonsynonymous sequence variants. Twenty-one were rare variants with minor allele frequency <1%, including 1 frameshift and 1 nonsense mutation (Online Table  I ). Ten of these variants were not found in public databases. Previously identified APOL1 alleles, rs73885319 (p.S342G), rs60910145 (p.I384M), which together are denoted G1, and rs71785313 (deletion of p.N388 and p.Y389; denoted G2) had minor allele frequency of 23%, 22%, and 14%, respectively. We also identified 16 individuals with an allele consisting of p.S342G without p.I384M, unlike the G1 allele, which we designated G1a. Among 284 JHS participants with 2 APOL1 risk alleles, 40% were G1 homozygotes, 14% were G2 (rs71785313) homozygotes, and 46% were compound G1/G2 heterozygotes. There were no significant differences in the baseline distribution of age, sex, smoking status, BMI, type 2 diabetes mellitus prevalence, hypertension prevalence, total cholesterol, and LDL cholesterol (LDL-C) among JHS participants with or without APOL1 risk alleles (Table 1 , Online Table II) . Previously reported associations between the common APOL1 G1 and G2 risk alleles and CKD were replicated among JHS subjects. 6, 20, 21 Thirty-six percent of JHS participants with 2 risk alleles had CKD compared with 18% of individuals with no risk alleles (P=2.4×10 −6 and Online Table III ). The association between CKD and these APOL1 genotypes was robust to adjusting for age, sex, BMI, diabetes mellitus status, hypertension covariates, LDL-C, HDL-C, and principal component analysis vectors 1 and 2 to account for African American population admixture (Online Table IV ). These APOL1 risk alleles were also associated with earlier onset kidney disease and dialysis with a Cox proportional hazard model (P=0.005 and P=0.04, respectively; Online Figure II) .
We next considered whether APOL1 G1 and G2 alleles were associated with increased risk of CVD, defined as a composite end point of myocardial infarction, stroke, or therapeutic surgical or endovascular interventions. JHS subjects with 2 APOL1 risk alleles had a 2-fold increased risk in these CVD events compared with individuals with no risk alleles (odds ratio, 2.17; P=9.4×10 −4 ; Table 2 ). Increased risk for these events was robust in a Cox proportional hazard model adjusted for traditional CVD risk factors (age, sex, BMI, diabetes mellitus status, hypertension status, smoking status, LDL-C, and HDL-C), including CKD (P=0.029; Figure 2A ). Substratification of events revealed a 2-fold increased risk for stroke (P=0.02) and cardiovascular surgery (P=0.015) as well as an 8-fold increased risk for endovascular catheterization (P=0.006; Online Table V) .
To better establish CVD risk among individuals carrying APOL1 risk alleles, we performed replication analyses in African American participants in the WHI, a randomized control trial of postmenopausal hormone therapy in healthy women. WHI enrollment excluded individuals with existing medical conditions, such as CKD, or individuals with a predicted survival of <3 years. The frequency of African American WHI participants with 2 APOL1 risk alleles was comparable with the frequency in JHS participants (P=0.6) and was in Hardy-Weinberg equilibrium. WHI participants had less CKD, based on estimated glomerular filtration rate and dialysis status (Online Table VI ), in comparison with JHS participants. We attribute this difference to the WHI enrollment exclusion criteria. However, we observed an association in WHI participants with 2 APOL1 risk alleles and estimated glomerular filtration rate (P=0.04) and hemoglobin (P=0.01), findings that may suggest subclinical renal impairment (Online Table VII ).
After controlling for age, BMI, diabetes mellitus status, and hypertension, WHI participants with 2 APOL1 risk alleles had Figure 2B , and Online Table VIII) . Importantly, CKD incidence in these individuals was not statistically discernable from baseline (Online Table VI ), an observation that likely reflected trial exclusion criteria (eg, significant renal disease and conditions that cause CKD). These findings suggest that individuals with APOL1 risk genotypes, even those without clinically significant kidney disease, have significantly increased risk for CVD. To further elucidate the pathophysiology underlying this increased cardiovascular risk, we considered a diverse set of intermediate cardiovascular phenotypes in the JHS and WHI studies including type 2 diabetes mellitus status, hypertension status, measures of left ventricular geometry or function (left ventricular hypertrophy and left ventricular dilatation studied as dichotomous phenotypes or quantitative phenotypes), hematocrit, blood glucose levels, cholesterol, and LDL-C (Online Tables II and VII, Online Figure III) . APOL1 risk alleles were not associated with any of these intermediate phenotypes.
Notably, we observed no association between APOL1 risk allele status and the inflammatory marker C-reactive protein (P=0.87) in JHS participants after controlling for BMI, sex, age, diabetes mellitus, hypertension, smoking status, and renal function. In addition, among JHS participants who had cardiac computerized tomographic imaging, APOL1 risk allele status was associated with decreased Agatston scores (a measurement of coronary artery calcium) 22 in the left main coronary artery (β, −6.04; P=0.019). This association remained even when individuals with CKD were removed from the data set (β, −6.2; P=0.024). Hence, the risk conferred by APOL1 may not be captured by conventional cardiovascular risk factors.
We also sought to determine whether the 2 APOL1 risk alleles conferred distinct CKD and CVD phenotypes. The risk for CKD and albuminuria in G2/G2 individuals was reduced compared with G1/G1 individuals (Online Table III ). Moreover, G1 homozygote carrier status was associated with reduced hematocrit (P<0.005; coefficient, −1.04), whereas G2 homozygotes had no association with hematocrit (P=0.5; coefficient, −0.4), findings that imply allele differences may result in different degrees of kidney function impairment (Online Table II ). In contrast, individuals with a G2/G2 risk were at higher risk for stroke (Online Table V ) and had decreased total cholesterol and HDL-C, whereas G1/G1 individuals were not associated with these phenotypes (Online Table II) .
A robust evaluation of rare and often unique APOL1 variants (Online Table I ) was hampered by small numbers, which reduced overall power to detect an effect. Fourteen individuals had a single rare APOL1 variant unaccompanied by the more common risk alleles, and 12 individuals had a single rare APOL1 variant in combination with 1 common risk allele. Three individuals had a single rare APOL1 variant in combination with 2 risk alleles, whereas 1 individual had multiple rare APOL1 variants with 2 risk alleles. The risk conferred by single rare variant either with or without a single APOL1 risk allele did not significantly influence CKD, CVD, or other phenotypes and the outcomes described above (Online Table IX ).
Discussion
Two major APOL1 alleles G1 and G2 that substantially increase the burden of renal disease and dialysis-dependent CKD also increase the risk for CVD in African Americans (JHS and WHI combined, P=8.5×10 −5 ). We demonstrate that APOL1 risk alleles impact CVD among participants in the JHS, an unselected community-based cohort. Importantly, we show in an unrelated cohort that the association of APOL1 alleles and CVD risk is independent of renal disease. These data support epidemiological evidence 4 that the differential burden of CVD in African Americans is based on ancestry that is unexplained by physiological risk factors.
Understanding APOL1 biology will be critical to elucidating the mechanisms by which APOL1 risk alleles promote CVD. Notably, our analyses uncovered distinct CVD phenotypes among individuals with either common APOL1 risk alleles. For example, in comparison with G1/G1, individuals with G2/G2 alleles had lower risk for CKD but higher risk for stroke, decreased total cholesterol, and HDL-C (Online Tables  II and V) . We hypothesize that the G1 allele, which contains missense residues, and the G2 allele, which deletes amino acids in the C-terminal domain, may convey distinct biological interactions that may incite distinct molecular processes and account for divergent phenotypes.
Atherosclerotic disease contributed to an increased CVD burden among APOL1 risk allele carriers in the JHS and WHI participants (Online Figure III) . Because inflammation and immunity play crucial roles in atherosclerosis, 23 we speculate that APOL1 impacts atherosclerosis through these pathways. We found no association between C-reactive protein levels and APOL1 risk alleles after controlling for multiple parameters; as such, the CVD risk conferred by APOL1 variants may be mediated through other distinct mechanisms. APOL1 risk allele status was also associated with decreased Agatston scores. Although the precise connection between Agatston scores and cardiovascular events remains to be defined, higher Agatston scores are correlated with increased stable atherosclerotic plaque. 24 In contrast, atherosclerotic CVD is thought to stem from unstable atherosclerotic plaque. 25, 26 Whether and how APOL1 participates in atherosclerotic plaque formation and stability remains to be determined. APOL1 also has specific functions (formation of anionic pores in the parasite lysosomal membranes, causing lysis) in innate immune responses to Trypanosoma brucei brucei 6 that may also be relevant to removal of proatherosclerotic cells. For example, inefficient removal of macrophage-derived foam cells from vascular beds promotes the accumulation of cellular debris and extracellular lipids which contributes to the formation of necrotic plaques. 27 In addition, as a component of HDL, APOL1 might also participate in anti-inflammatory actions that HDL has on endothelial cells, leukocytes, and vascular smooth muscles. 13 Notably, the abundance of APOL1 in dense HDL3 particles strongly correlates with the capacity of HDL to attenuate LDL oxidation. 9 The substantial morbidity and mortality associated with CKD and CVD, alone and in combination, 28 underscores the importance of identifying and treating high-risk individuals. Recent guidelines 29 recommend screening kidney transplantation candidates for CVD based on the presence of multiple risk factors (diabetes mellitus, previous CVD, dialysis for >1 year, left ventricular hypertrophy, aged >60 years, smoking, hypertension, and dyslipidemia). Our conclusion that APOL1 risk alleles are associated with accelerated CVD, as well as with CKD, indicates that incorporation of analyses of these variants in African American patients may provide important information to improve their clinical care.
What Is Known?
• African Americans have greater risk for developing chronic kidney disease (CKD) and cardiovascular disease (CVD) than Americans of European ancestry. • Genome-wide association studies identified 2 risk alleles (G1 and G2) in apolipoprotein L1 (APOL1) that significantly increased the burden of CKD in African Americans.
What New Information Does This Article Contribute?
• The APOL1 risk alleles G1 and G2 also significantly increase the burden of CVD in African Americans. • The increased CVD risk conveyed by APOL1 alleles is independent of CKD and traditional risk factors for atherosclerosis.
Two risk alleles in APOL1, which convey resistance to sleeping sickness and are found among individuals of African but not European ancestry, account for a substantial burden of CKD found in African Americans. Because Americans of African ancestry also have higher risks of CVD than individuals of European descent, we asked whether the 2 APOL1 risk alleles were associated with increased risk for atherosclerosis in 2 separate cohorts. Among 1959 randomly selected African American participants from the Jackson Heart Study with 2 risk alleles, we observed increased risk for atherosclerotic CVD events which was independent of CKD and traditional atherosclerotic risk factors. We replicated this novel and independent association of APOL1 alleles and atherosclerotic CVD in 749 participants in the Women's Health Initiative. The substantial morbidity and mortality associated with CKD and CVD, alone and in combination, underscores the importance of identifying and treating high-risk individuals. We suggest that ascertaining APOL1 risk allele status in African Americans may provide important information to guide treatments that reduce the risk of CVD.
Novelty and Significance
